Clinical Trials Browser

Phase 1/2 × Recruiting × Bile Duct Neoplasms × Clear all

Bile Duct Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Cholangiocarcinoma

NCT05849480 2026-02-05

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Phase 1/2 Recruiting

60 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms

NCT05150691 2026-01-28

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

796 enrolled

BreastGastrointestinalGynecologicThoracic

Bile Duct Neoplasms, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05874414 2026-01-22

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Phase 1/2 Recruiting

74 enrolled

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

Clinical Trials

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma